Sputnik Light Vaccine Found 85% Effective

The Moscow-based Russian Direct Investment Fund (RDIF) announced data from a study conducted by the Institute of Virology of the National University of Cordoba located in Argentina and the authorities of Cordoba, which confirm the neutralizing effect of the two-component Sputnik V vaccine against the Brazilian strain of SARS-CoV-2 beta coronavirus, first identified in the city of Manaus.

In particular, the study confirmed 99.65% of individuals developed IgG antibodies to coronavirus on the 42nd day after receiving the second injection of the Sputnik V vaccine.

And 85.5% of individuals developed IgG antibodies to coronavirus on the 14th day after receiving the first injection of Sputnik V.

The RDIF recently announced the availability of the Sputnik LIght vaccine, which is a single-dose version.

The RDIF was founded in 2011 to invest in the equity capital of companies primarily in Russia, together with leading foreign financial and strategic investors.